Pan-cancer analysis reveals CHRM2 as a biomarker for cancer prognosis and immunotherapy

被引:0
|
作者
Huang, Qingming [1 ,2 ,3 ]
Su, Zhengwei [1 ,2 ,3 ]
Tang, Han [1 ,2 ,3 ]
Ban, Chengjie [1 ,2 ,3 ]
Xie, Huadong [1 ,4 ]
Liao, Tianling [1 ,5 ]
Liao, Kangji [1 ,2 ]
Cheng, Zhi [1 ,4 ]
Yi, Xian lin [1 ,2 ]
机构
[1] Huazhong Univ Sci & Technol, Maternal & Child Hlth Hosp Hubei Prov, Tongji Med Coll, Dept Urol, Wuhan, Peoples R China
[2] Guangxi Med Univ, Wuming Hosp, Dept Urol, Nanning, Guangxi, Peoples R China
[3] Guangxi Med Univ, Canc Hosp, Dept Urol, Nanning, Guangxi, Peoples R China
[4] Guangxi Med Univ, Affiliated Hosp 2, Dept Urol, Nanning, Guangxi, Peoples R China
[5] Guangxi Med Univ, Affiliated Hosp 1, Dept Tradit Chinese Med, Nanning, Guangxi, Peoples R China
来源
GENETICS AND MOLECULAR RESEARCH | 2024年 / 23卷 / 03期
关键词
CHRM2; Pan-cancer; Prognosis; Immune infiltration; INHIBIT CELL-PROLIFERATION; C-MET; CARCINOMA; MIGRATION;
D O I
10.4238/gmr2343
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: CHRM2 is a member of the muscarinic acetylcholine receptor gene, which plays an important role in many cancers. Methods: Differential expression of CHRM2 across cancers was analyzed using The Cancer Genome Atlas (TCGA) database, and survival analysis of CHRM2 was performed using the Kaplan-Meier method. Spearman correlation analysis was used to study the correlation between CHRM2 and tumor mutation burden and microsatellite instability, and immune cell infiltration in tumor tissues were analyzed by the ESTIMATE and CIBERSORT algorithms. The biological role of CHRM2 in cancer was investigated by gene set enrichment analysis, and drug sensitivity analysis was conducted using the CellMiner database. Results: CHRM2 expression was downregulated in most cancers, and low CHRM2 expression was associated with better prognosis, especially in BLCA and COAD. CHRM2 expression correlated significantly with clinical stage, TMB, MSI, and a variety of immune cells and immune factors. GSEA showed that CHRM2 was enriched in many functions and pathways, and drug sensitivity analysis showed that CHRM2 correlated positively with several c-Met inhibitors. Conclusion: CHRM2 may be a prognostic indicator, a potential biomarker and a therapeutic target for pan-cancer, especially BLCA and COAD.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] Pan-cancer analysis reveals IGFL2 as a potential target for cancer prognosis and immunotherapy
    Wang, Yuqi
    Yuan, Hongwei
    Yue, Genquan
    Zhao, Lingyan
    Xia, Yuan
    Zhang, Nan
    Li, Hailing
    Liu, Dongyang
    Su, Yubo
    Wang, Haisheng
    Gao, Yumin
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [2] Pan-cancer analysis reveals IGFL2 as a potential target for cancer prognosis and immunotherapy
    Yuqi Wang
    Hongwei Yuan
    Genquan Yue
    Lingyan Zhao
    Yuan Xia
    Nan Zhang
    Hailing Li
    Dongyang Liu
    Yubo Su
    Haisheng Wang
    Yumin Gao
    Scientific Reports, 13
  • [3] Comprehensive pan-cancer analysis reveals EPHB2 is a novel predictive biomarker for prognosis and immunotherapy response
    Xu, Shengshan
    Zheng, Youbin
    Ye, Min
    Shen, Tao
    Zhang, Dongxi
    Li, Zumei
    Lu, Zhuming
    BMC CANCER, 2024, 24 (01)
  • [4] Comprehensive pan-cancer analysis reveals SIRT5 is a predictive biomarker for prognosis and immunotherapy response
    Ji, Yacong
    Li, Chongyang
    Wan, Sicheng
    Zhang, Kui
    Liu, Yaling
    Shi, Shaomin
    FUNCTIONAL & INTEGRATIVE GENOMICS, 2024, 24 (02)
  • [5] Comprehensive pan-cancer analysis reveals SIRT5 is a predictive biomarker for prognosis and immunotherapy response
    Yacong Ji
    Chongyang Li
    Sicheng Wan
    Kui Zhang
    Yaling Liu
    Shaomin Shi
    Functional & Integrative Genomics, 2024, 24
  • [6] A Pan-Cancer Analysis Reveals CLEC5A as a Biomarker for Cancer Immunity and Prognosis
    Chen, Rui
    Wu, Wantao
    Chen, Si-Yu
    Liu, Zheng-Zheng
    Wen, Zhi-Peng
    Yu, Jing
    Zhang, Long-Bo
    Liu, Zaoqu
    Zhang, Jian
    Luo, Peng
    Zeng, Wen-Jing
    Cheng, Quan
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [7] Pan-cancer analysis identifies the IRF family as a biomarker for survival prognosis and immunotherapy
    Xu, Hua-Guo
    Chen, Can
    Chen, Lin-Yuan
    Pan, Shiyang
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2024, 28 (03)
  • [8] Pan-cancer analysis of ADAMs: A promising biomarker for prognosis and response to chemotherapy and immunotherapy
    Ma, Bo
    Yu, Riyue
    FRONTIERS IN GENETICS, 2023, 14
  • [9] Comprehensive Pan-Cancer Analysis of Senescence With Cancer Prognosis and Immunotherapy
    Zhao, Qinfei
    Hu, Weiquan
    Xu, Jing
    Zeng, Shaoying
    Xi, Xuxiang
    Chen, Jing
    Wu, Xiangsheng
    Hu, Suping
    Zhong, Tianyu
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2022, 9
  • [10] Comprehensive pan-cancer analysis reveals NUSAP1 is a novel predictive biomarker for prognosis and immunotherapy response
    Zheng, Hong
    Wang, Minghao
    Zhang, Shiyu
    Hu, Dongxue
    Yang, Qiaoyun
    Chen, Ming
    Zhang, Xia
    Zhang, Yi
    Dai, Jigang
    Liou, Yih-Cherng
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2023, 19 (14): : 4689 - 4708